Filing Overview
Registrant: Jupiter Wellness, Inc. The provided metadata identifies BONK, Inc., but the filing itself names Jupiter Wellness, Inc. as the registrant. The Form 8-K was filed April 6, 2022, under Item 7.01 (Regulation FD Disclosure).
Business Context and Reporting Period
The company announced publication of clinical-study results for JW-100, a lotion formulation intended to treat atopic dermatitis, commonly known as eczema. The filing reports an event date of April 6, 2022 and does not provide quarterly or annual financial results.
Key Financial Metrics
- Revenue, profit, cash flow, margins, debt, and liquidity: Not provided in the filing.
- Financial statements: None were included in the provided filing text.
- Capital structure: The filing identifies common stock trading under JUPW and warrants exercisable at $8.50 per share trading under JUPWW on Nasdaq.
Material Developments
- The clinical study included 57 patients divided into three treatment groups.
- The group receiving JW-100 demonstrated statistically significant improvements in atopic dermatitis after 14 days of use.
- The filing does not provide the statistical measures, effect sizes, control-group results, detailed methodology, or complete clinical data in the supplied text.
Outlook, Risks, and Unusual Items
The filing contains forward-looking statements and cautions that actual results may differ materially due to operational and financial risks and uncertainties. The company does not undertake to update forward-looking statements except as required by law.
The press release describing the clinical results was filed as Exhibit 99.1. No revenue guidance, commercial launch timing, regulatory approval status, financing plans, contingencies, or other outlook information is provided in the filing text.
Investor Verification Items
- Confirm the registrant identity because the request metadata names BONK, Inc., while the filing names Jupiter Wellness, Inc.
- Review Exhibit 99.1 for the complete clinical-study results, statistical significance measures, treatment-group details, and study limitations.
- Verify whether the JW-100 results have any regulatory or commercial implications; the filing does not state that the product has been approved.
- Assess the company’s financial condition separately, as this Form 8-K provides no financial metrics or liquidity information.